page_content stringlengths 12 2.63M | metadata unknown |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. All are indicated
for major depression. Several of these medications are also prescribed "off-label" for other psychiatric disorders, meaning the prescriber is using them for purposes other than what they were approved f... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Selective Serotonin Reuptake Inhibitors**",
"token_count": 897,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Sexual dysfunction is one main reason why clients may elect to stop taking SSRIs. Impotence, delayed or absent ejaculation or orgasm, and decreased libido can be side effects of these medications. This can be managed in several ways: reduction of the dose, taking drug holidays, or adding a drug that can overcome the pr... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Adverse Effects and Contraindications**",
"token_count": 897,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Similar to most SSRIs, SNRIs should not be taken until the client has stopped taking MAOIs for at least 14 days. This is to decrease the risk of serotonin syndrome.
Neonatal syndrome can occur when duloxetine is taken late in pregnancy. This syndrome is characterized by irritability, high-pitched cry, tremor, respira... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Adverse Effects and Contraindications**",
"token_count": 814,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
NDRIs have several CNS stimulant effects including agitation, anxiety, excitement, increased motor activity, and restlessness. These effects usually occur during the first few days of treatment. (The client may require a sedative for the first few days.) These effects occur because this drug is similar in structure to ... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Adverse Effects and Contraindications**",
"token_count": 960,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Monoamine oxidase inhibitors (MAOIs) are third-line agents for treating depression. MAOIs are not often used in practice today, mainly because of the numerous food and drug interactions that produce severe hypertension. Blood pressure could be elevated enough to cause a stroke or myocardial infarction. MAOIs are used w... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Monoamine Oxidase Inhibitors**",
"token_count": 368,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Some drugs work just as well for depressive symptoms but do not fit into the criteria of other drug classes. They include:
- Mirtazapine: Used to treat major depressive disorder.
- Trazodone hydrochloride: This drug is a serotonin 2 antagonist/reuptake inhibitor. It increases the amount of serotonin available. It is ... | {
"Header 1": "CHAPTER 13 Psychopharmacologic Drugs",
"Header 2": "**Miscellaneous Antidepressants**",
"token_count": 430,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Read the following clinical scenario to answer the questions that follow.
Jadalyn Sanchez is a 21-year-old female student who arrives at the university's student health center with complaints of frequent crying throughout the day and lack of motivation or interest in being with friends or engaging in activities she u... | {
"Header 1": "CASE STUDY",
"token_count": 236,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 13.2.1 Identify the characteristics of drugs used to treat psychosis.
- 13.2.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of drugs used to treat psychosis.
- 13.2.3 Describe nursing implications for drugs used to treat ... | {
"Header 1": "CASE STUDY",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 532,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- Schizophrenia in children often presents with more intense clinical manifestations and has a more chronic course.
- • The American Academy of Child and Adolescent Psychiatry has established current practice guidelines that advocate for high-quality assessment of the child who is receiving antipsychotics. The purpose ... | {
"Header 1": "CASE STUDY",
"Header 2": "Schizophrenia in Children",
"token_count": 358,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
First-generation antipsychotics are frequently referred to as "neuroleptics" because of the increased risk of producing extrapyramidal neurologic effects, including **pseudoparkinsonism**, **dystonia** (spasms of the tongue, back, legs, and neck), **akathisia** (not being able to sit still), and **tardive dyskinesia** ... | {
"Header 1": "CASE STUDY",
"Header 2": "Antipsychotics",
"token_count": 442,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
First-generation antipsychotics are classified by their potency (strength). The level of potency (low, medium, or high) refers to the concentration of the drug needed to produce a given response. Keep in mind that this is different from efficacy. All first-generation agents have the same ability to relieve symptoms of ... | {
"Header 1": "CASE STUDY",
"Header 2": "**First-Generation (Typical) Antipsychotics**",
"token_count": 840,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Most of the ADRs are related to these drugs' anticholinergic properties, including blurred vision, dry mouth, constipation, urine retention, nasal congestion, and photophobia. Arrhythmias can be caused by the dopamineblocking effects or prolongation of the QTc interval, which could lead to fatal arrhythmias. Prolactin ... | {
"Header 1": "CASE STUDY",
"Header 2": "**First-Generation (Typical) Antipsychotics**",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 445,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
(Source: ISMP, 2023)
[Table 13.13](#page-417-0) is a drug prototype table for first-generation antipsychotics featuring haloperidol. It lists drug class, mechanism of action, adult and pediatric dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.
| Drug Clas... | {
"Header 1": "CASE STUDY",
"Header 2": "Similarly Named Drugs Associated with First-Generation Antipsychotics",
"Header 3": "antidiabetic).",
"token_count": 685,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The second-generation antipsychotics, also known as atypical antipsychotics, are the drugs of choice. This is especially true for clients who are newly diagnosed. The atypical antipsychotics block both dopamine and serotonin receptors. This class of antipsychotics has a broader range of action than the first-generation... | {
"Header 1": "CASE STUDY",
"Header 2": "**Second-Generation (Atypical) Antipsychotics**",
"token_count": 1287,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The nurse should do the following for clients who are taking antipsychotics:
- Watch carefully for developmental progress in children.
- Monitor for symptoms of schizophrenia.
- Obtain baseline physical assessment and relevant tests including an electrocardiogram, CBC, electrolytes, liver and renal function tests, li... | {
"Header 1": "CASE STUDY",
"Header 2": "SAFETY ALERT",
"Header 3": "**Nursing Implications**",
"token_count": 482,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- Drink adequate amounts of water (at least 64 ounces/day or other prescribed amount), especially during hot weather.
- Have a total understanding that full therapeutic effects will not occur immediately; it may take several weeks to be able to experience effects.
- Obtain weekly blood tests to determine safe and effec... | {
"Header 1": "CASE STUDY",
"Header 2": "**The client taking an antipsychotic should:**",
"token_count": 296,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 13.3.1 Identify the characteristics of drugs used to treat bipolar disorder.
- 13.3.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of drugs used to treat bipolar disorder.
- 13.3.3 Describe nursing implications for drugs ... | {
"Header 1": "CASE STUDY",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 355,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Lithium is a naturally occurring metallic salt. It is used mainly to treat and prevent mania. It has historically been the "gold standard" mood stabilizer, effectively controlling manic episodes as well as decreasing the frequency and intensity of manic cycles (Volkmann et al., 2020). Lithium has a narrow margin of saf... | {
"Header 1": "CASE STUDY",
"Header 2": "**Lithium**",
"token_count": 314,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Lithium is excreted through the kidneys unchanged; therefore, adequate renal function is essential. Because lithium is tied to sodium resorption, any drug that affects sodium balance may alter lithium concentrations, leading to either treatment failure or toxicity. Examples include diuretics, NSAIDs, and angiotensin-co... | {
"Header 1": "CASE STUDY",
"Header 2": "**Lithium**",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 894,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Selected antiseizure medications can be used to treat mood disorders, usually in combination with other medications. Please refer to [Anticonvulsant Drugs and Drugs to Treat Epilepsy, Migraine Headaches, and](#page-364-1) [Intracranial Emergencies](#page-364-1) for a more detailed discussion of antiseizure medications.... | {
"Header 1": "CASE STUDY",
"Header 2": "**Antiseizure Medications**",
"token_count": 536,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- Contact the health care provider with the first signs of rash if taking carbamazepine or lamotrigine.
- Notify the health care provider with unusual and easy bruising, blood in the urine or stool, fever, sore throat, right upper quadrant pain, and jaundice.
- Consider an additional or alternate form of contraception ... | {
"Header 1": "CASE STUDY",
"Header 2": "CLIENT TEACHING GUIDELINES",
"Header 3": "**The client taking a mood stabilizer should:**",
"token_count": 232,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 13.4.1 Identify the characteristics of drugs used to treat anxiety and sleep disorders.
- 13.4.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of drugs used to treat anxiety and sleep disorders.
- 13.4.3 Describe nursing i... | {
"Header 1": "CASE STUDY",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 732,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Flumazenil is a specific benzodiazepine receptor antagonist and is beneficial in reversing the effects of benzodiazepine. It should be available for use as needed to reverse the effects of benzodiazepines administered for sedation. It is also used emergently to treat benzodiazepine overdose.
(Source: Shoar et al., 20... | {
"Header 1": "CASE STUDY",
"Header 2": "Reversal Agent for Benzodiazepine Toxicity",
"token_count": 1033,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Due to the prolonged half-life, both therapeutic and adverse effects are more likely to occur after 3 days of therapy. A client with a history of psychosis should avoid taking benzodiazepines due to the potential exacerbation of symptoms. Acute narrow-angle glaucoma is also a contraindication because this drug class ca... | {
"Header 1": "CASE STUDY",
"Header 2": "Reversal Agent for Benzodiazepine Toxicity",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 267,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Age
- Children: Great caution needs to be given when administering benzodiazepines or sedative-hypnotics to children because their response to the drug is very unpredictable. Of the benzodiazepines, only chlordiazepoxide, clonazepam, lorazepam, midazolam, and diazepam have established pediatric dosages. Children must... | {
"Header 1": "CASE STUDY",
"Header 2": "SPECIAL CONSIDERATIONS",
"token_count": 735,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
This classification produces sleep. Clients may receive nonbenzodiazepine sedative-hypnotics prior to diagnostic or surgical procedures or take them for sleepless nights. These drugs should only be taken when insomnia is causing distress and nonpharmacologic measures have been ineffective. They should not be taken ever... | {
"Header 1": "CASE STUDY",
"Header 2": "**Nonbenzodiazepine Sedative-Hypnotics**",
"token_count": 426,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Eszopiclone should be avoided in older adults.
(Source: American Geriatrics Society, 2023)
- Ramelteon (not a controlled substance): Ramelteon is a melatonin receptor agonist used long-term for chronic insomnia. This drug is beneficial for decreasing sleep latency. ADRs specific to this drug include hormonal effect... | {
"Header 1": "CASE STUDY",
"Header 2": "Beers Criteria®",
"token_count": 1127,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Clients can experience **angioedema** if they are allergic to any of the components in the drug. These drugs are metabolized by the liver, so they should be avoided by anyone with severe hepatic failure. Lower doses should be administered for those with mild to moderate hepatic insufficiency and in the older adult. Gla... | {
"Header 1": "CASE STUDY",
"Header 2": "Beers Criteria®",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 323,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Do not confuse:
- Lunesta (nonbenzodiazepine sedative-hypnotic) with Neulasta (bone marrow stimulant)
- Rozerem (nonbenzodiazepine sedative-hypnotic) with Razadyne (acetylcholinesterase inhibitor for dementia)
(Source: ISMP, 2023)
[Table 13.22](#page-432-0) is a drug prototype table for nonbenzodiazepine sedative... | {
"Header 1": "CASE STUDY",
"Header 2": "Similarly Named Drugs Associated with Nonbenzodiazepine Sedative-Hypnotics",
"token_count": 641,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The nurse should do the following for clients who are taking anxiolytics or sedative-hypnotics:
- Help the client to identify triggers and develop coping mechanisms to help with reducing anxiety.
- Assess the client's sleep patterns.
- Monitor heart rate, blood pressure, respiratory rate, temperature, and weight.
- A... | {
"Header 1": "CASE STUDY",
"Header 2": "**Nursing Implications**",
"token_count": 281,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 13.5.1 Identify the characteristics of drugs used to treat attention deficit disorders and narcolepsy.
- 13.5.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of drugs used to treat attention deficit disorders and narcoleps... | {
"Header 1": "CASE STUDY",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 651,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
CNS stimulants are the mainstay of ADHD therapy. Although treating ADHD with a stimulant seems paradoxical, these drugs give the client the ability to maintain attention and focus on one activity for a longer period of time. These drugs redirect and excite the arousal stimuli from the RAS. They also help clients increa... | {
"Header 1": "CASE STUDY",
"Header 2": "**Central Nervous System Stimulants**",
"token_count": 1944,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
A client must use CNS stimulants with caution when pregnant and taking stimulants. Premature delivery and low birth weight have occurred in infants born to a parent taking these drugs.
Stimulants are contraindicated in glaucoma, hyperthyroidism, and the spectrum of cardiovascular diseases because they can exacerbate ... | {
"Header 1": "CASE STUDY",
"Header 2": "Similarly Named Drugs Associated with CNS Stimulants",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 1183,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
These alternative drugs for ADHD and narcolepsy are not associated with the many cardiac and systemic stimulatory effects experienced with the CNS stimulants. They are preferable in clients who are unable to tolerate the stimulatory effects of the other drugs. The most common CNS nonstimulants are:
- Atomoxetine: Thi... | {
"Header 1": "CASE STUDY",
"Header 2": "**CNS Nonstimulants**",
"token_count": 1224,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Adverse effects seen with atomoxetine are mainly related to its anticholinergic effects. These include dry mouth, blurred vision, nausea, constipation, and urine retention. Guanfacine and clonidine can cause sedation, severe hypotension, and bradycardia. Antihypertensives and CNS depressants are contraindicated with th... | {
"Header 1": "CASE STUDY",
"Header 2": "**CNS Nonstimulants**",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 214,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Do not confuse Intuniv (CNS nonstimulant) with Invega (antipsychotic).
(Source: ISMP, 2023)
[Table 13.26](#page-439-0) is a drug prototype table for CNS nonstimulants featuring clonidine. It lists drug class, mechanism of action, adult and pediatric dosage, indications, therapeutic effects, drug and food interactio... | {
"Header 1": "CASE STUDY",
"Header 2": "Similarly Named Drugs Associated with CNS Nonstimulants",
"token_count": 466,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The nurse should do the following for clients who are taking CNS stimulants and nonstimulants:
- Screen and monitor client's cardiovascular risk factors, such as family history, smoking, elevated lipids, hypertension, diabetes mellitus, and obesity.
- Assess client's psychiatric history.
- Measure and document blood ... | {
"Header 1": "CASE STUDY",
"Header 2": "**Nursing Implications**",
"token_count": 207,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- **affective** relates to mood, feelings, emotion, and attitudes
- **akathisia** continuous restlessness, inability to sit still; clients may say they feel hyperactive deep inside their body
- **angioedema** fluid buildup in the deeper layers of the skin causing edema; considered a type of allergic reaction
- **antero... | {
"Header 1": "CASE STUDY",
"Header 2": "**Key Terms**",
"token_count": 929,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
14.1 [Introduction to Pain](#page-444-2) 14.2 [Nonopioid Analgesics](#page-447-0) 14.3 [Opioid Agonists and Antagonists](#page-452-0)
**INTRODUCTION** Pain is one of the most common reasons individuals seek medical treatment, and it can arise from a number of sources, including trauma, cancer, and autoimmune and othe... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**CHAPTER OUTLINE**",
"token_count": 213,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Pain** is generally defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage" (Raja et al., 2020). Pain is, by nature, a subjective experience that the client describes to the health care provider, so many health care professiona... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**Pain**",
"token_count": 1157,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Nociception** is the term used to describe the processing of noxious stimuli by both the peripheral and central nervous systems. Pain is the client's subjective experience of this nociception. Nociception is a complex process that involves five steps: transduction, conduction, transmission, modulation, and perception... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**Pathophysiology of Pain**",
"token_count": 418,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 14.2.1 Identify the characteristics of nonopioid analgesic drugs used to treat pain.
- 14.2.2 Explain the indications, actions, adverse reactions, and contraindications of nonopioid analgesic drugs used to treat pain.
- 14.2.3 Describe the nursing implications of n... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 557,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Acetaminophen is a common over-the-counter nonopioid analgesic. It is one of the most popular analgesics due to its low cost, efficacy in treating mild to moderate pain, and excellent safety profile when used within the
recommended dosages. Acetaminophen's complete mechanism of action to relieve pain is not currently... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**Acetaminophen**",
"token_count": 237,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Aspirin, ibuprofen, and naproxen sodium are classified as **nonsteroidal anti-inflammatory drugs (NSAIDs)**. This classification means they possess analgesic, antipyretic, and anti-inflammatory actions without belonging to the group of medications known as the glucocorticoids (e.g., prednisone and dexamethasone, which ... | {
"Header 1": "CHAPTER 14 Pain Response Drugs",
"Header 2": "**Aspirin, Ibuprofen, and Naproxen Sodium**",
"token_count": 350,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Opioid agonists** have been in use for thousands of years. Opioids originated from the opium poppy, Papaver somniferum, from which naturally occurring opioids such as heroin, codeine, and morphine are derived. Since the discovery of the potent analgesic effects of these medications, other opioids have been developed,... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Opioid Agonists**",
"token_count": 357,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Codeine is one of the naturally occurring opioids derived from the opium poppy. It is most often given orally for mild to moderate pain. For codeine to be effective, it must be converted to morphine in the liver via the enzyme **cytochrome P450 2D6** (CYP2D6). Because individuals may produce more or less CYP2D6, client... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Opioid Agonists**",
"Header 3": "**Codeine**",
"token_count": 220,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Oxycodone is a semisynthetic opioid commonly used orally to treat moderate to severe pain. It is frequently used because of its favorable side effect profile compared with other agents such as morphine (for instance, oxycodone causes less itching).
Oxycodone comes in a variety of dosage forms, including immediate- an... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Fentanyl**",
"Header 3": "**Oxycodone**",
"token_count": 752,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Adverse effects of opioid therapy can range from general gastrointestinal upset to life-threatening respiratory depression. The most common are gastrointestinal effects, including nausea, vomiting, and constipation. Nearly all clients receiving chronic opioid therapy will develop constipation, so nurses should assess f... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Fentanyl**",
"Header 3": "**Adverse Effects and Contraindications**",
"token_count": 442,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Opioid agonists expose clients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each client's risk prior to prescribing and reassess all clients regularly for the development of these behaviors and conditions.
Serious, life-threatening, or fatal respira... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "FDA BLACK BOX WARNING",
"Header 3": "**Opioid Agonists**",
"token_count": 299,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Tolerance** is a phenomenon that occurs in clients taking opioid agonists chronically. As the body adapts to the presence of the drug, the client will become accustomed to some of the side effects, including sedation, and it may appear as if the dose that previously treated the client's pain is no longer adequate. Th... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Tolerance**",
"token_count": 240,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Opioid **addiction** (also called **opioid use disorder**) is a condition characterized by compulsive use of opioids, increased opioid tolerance, and withdrawal symptoms if the client does not continue taking an opioid agonist. This compulsion can be so strong in susceptible individuals that they will continue using op... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Tolerance**",
"Header 3": "**Addiction**",
"token_count": 377,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Naloxone hydrochloride is an opioid receptor antagonist that is used as an antidote in people experiencing signs and symptoms of opioid agonist overdose, including severe CNS and respiratory depression. Overdose may present as shallow or absent breathing, and the person may be unresponsive to any type of stimuli. Nalox... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Opioid Antagonists**",
"Header 3": "**Naloxone Hydrochloride**",
"token_count": 290,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Naltrexone hydrochloride is an opioid receptor antagonist. It is not often given for emergency reversal of opioid intoxication but is instead used for clients who want to abstain from opioid use. It is orally bioavailable, and when a client has been taking it orally, it will blunt the effects of opioids if the client r... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Opioid Antagonists**",
"Header 3": "**Naltrexone Hydrochloride**",
"token_count": 204,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- **acute pain** pain that is sudden in onset and is expected to last less than 1 month
- **addiction** a persistent, compulsive dependence on a substance or behavior despite known harm
- **antipyretics** medications used to treat fever **chronic pain** pain persisting longer than 3 months **conduction** the process of... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Key Terms**",
"token_count": 311,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- 15.1 [Introduction to Substance Use Disorders](#page-464-2)
- 15.2 [Opioid Use Disorder Drugs](#page-468-0)
- 15.3 [Alcohol Use Disorder Drugs](#page-474-0)
- 15.4 [Nicotine Use Disorder Drugs](#page-478-0)
**INTRODUCTION** Substance use disorders are a major public health concern in the United States and affect mi... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**CHAPTER OUTLINE**",
"token_count": 226,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The standard definition of a **substance use disorder** (SUD), from the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), is that it involves patterns of symptoms caused by using a substance that an
individual continues taking despite its negative effects (McNeely & Adam, 2020). This chapter... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Introduction to Substance Use Disorders**",
"token_count": 658,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
To understand the different aspects of SUDs and their treatments, it is important for the health care provider (HCP) to understand how these disorders begin and the physiologic changes that occur when using these substances. Key concepts for the HCP to understand are the early euphoric aspects of intoxication, leading ... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Overview of Substance Use and Abuse**",
"token_count": 268,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Intoxication** refers to the substance-specific physiologic effects that occur after exposure to a psychoactive substance (American Psychological Association, 2023). The effects of intoxication can vary widely depending on the mechanism of action of the specific substance the client is exposed to. For example, someon... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "SPECIAL CONSIDERATIONS",
"Header 3": "**Intoxication**",
"token_count": 277,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Physical dependence** refers to the homeostatic adaptation that occurs when the body is exposed to certain
substances over a prolonged period (American Psychological Association, 2023). This adaptation means that the body becomes used to having the effect of the drug, and when that drug is removed, the body will de... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "SPECIAL CONSIDERATIONS",
"Header 3": "**Physical Dependence**",
"token_count": 215,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Withdrawal** refers to physiologic and psychological consequences of discontinuation or reversal of a substance that the client has been using for a sufficient period. The degree of withdrawal symptoms that are experienced is determined by the substance used, dose, duration of use, and last time of exposure to the su... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "SPECIAL CONSIDERATIONS",
"Header 3": "**Withdrawal**",
"token_count": 212,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Treatment of substance use disorders is complex and challenging. Unfortunately, no single approach will work for every client. It is important to not manage a substance use disorder in a vacuum but instead consider all the unique circumstances that may affect the ultimate success of treatment. These circumstances can i... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Treatment Approaches for Substance Use Disorders**",
"token_count": 378,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Opioids are a class of drugs that activate the opioid receptors in the CNS. Opioids have been widely used for thousands of years and are derived from the opium poppy, Papaver somniferum. Opioids include many agents, including naturally occurring opioids such as heroin, codeine, and morphine, along with synthetically de... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Opioid Use**",
"token_count": 372,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Opioids produce many of their desired therapeutic effects and potentially life-threatening adverse effects via the opioid receptors, including the mu, delta, and kappa receptors. Opioid intoxication is classically described as a triad of symptoms consisting of reduced consciousness, slow and/or shallow breathing, and m... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Opioid Intoxication**",
"token_count": 317,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Opioid withdrawal occurs in clients using opioids for a chronic period who have abruptly discontinued the drug, or from rapid reversal of the drug's effect with an opioid antagonist (e.g., naloxone). The onset of opioid withdrawal will vary from a few seconds to minutes after administration of a dose of a reversal agen... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Opioid Withdrawal**",
"token_count": 232,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Naloxone is the prototypical mu opioid receptor antagonist used to rapidly reverse the life-threatening effects of opioid overdose. While naloxone is not used directly in the treatment of opioid use disorders, it is important that clients at risk for opioid overdose have quick and easy access to naloxone in case of acc... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Drugs Used to Treat Opioid Use Disorders**",
"Header 3": "**Naloxone**",
"token_count": 355,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Buprenorphine is a partial mu opioid receptor agonist that is designed to reduce the symptoms of opioid withdrawal and cravings in clients abstaining from opioid use. The inclusion of naloxone with oral preparations of buprenorphine may seem nonsensical given that naloxone has poor oral bioavailability, but this is don... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Drugs Used to Treat Opioid Use Disorders**",
"Header 3": "**Buprenorphine-Naloxone**",
"token_count": 208,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Methadone is a full mu opioid receptor agonist that has been used for many years to wean clients off opioids. Being a full agonist, methadone can help reduce or prevent opioid withdrawal symptoms and allow for a gradual tapering down of the methadone dose until the client no longer requires it. Methadone is used over o... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "**Drugs Used to Treat Opioid Use Disorders**",
"Header 3": "**Methadone**",
"token_count": 689,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
In the United States, there is a severe lack of specially trained health care practitioners able to provide OUD treatment with agents such as methadone. There has been a push recently to increase the ability for health care practitioners to treat clients with OUD in the primary care setting with agents such as buprenor... | {
"Header 1": "CHAPTER 15 Substance Use Disorder Treatment Drugs",
"Header 2": "X-Waiver Requirement",
"token_count": 215,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Alcohol, more specifically ethanol, is the byproduct of the fermentation of carbohydrates and is one of the most widely used psychoactive compounds in the world. While alcohol is legal to purchase and seen as a socially acceptable substance for recreational use, it is also a major contributor to significant morbidity a... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Alcohol Use**",
"token_count": 315,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Alcohol intoxication follows a predictable dose response in clients with low or no routine alcohol consumption. At low doses, alcohol lowers inhibitions and can cause a mild euphoria. At moderate doses, ethanol will cause ataxia (e.g., gait instability), slurred speech, and impaired memory. At higher doses, alcohol can... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Alcohol Intoxication**",
"token_count": 304,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Chlordiazepoxide falls into the category of drugs known as benzodiazepines. These drugs, like alcohol, work to enhance the actions of GABA to cause a general CNS depression. Benzodiazepines bind to the benzodiazepine receptor to allow GABA to bind to the receptor more readily, increasing its effects. Benzodiazepines ar... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Drugs Used to Treat Alcohol Use Disorders**",
"Header 3": "**Chlordiazepoxide**",
"token_count": 254,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Disulfiram is a drug that works by inhibiting the actions of the enzyme acetaldehyde dehydrogenase. In the liver, alcohol is first metabolized by the enzyme alcohol dehydrogenase, which converts it to acetaldehyde. Acetaldehyde is then further metabolized by acetaldehyde dehydrogenase. Acetaldehyde itself is a very irr... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Drugs Used to Treat Alcohol Use Disorders**",
"Header 3": "**Disulfiram**",
"token_count": 304,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Like chlordiazepoxide, lorazepam is a benzodiazepine used to treat anxiety and seizures and to control the symptoms of alcohol withdrawal. Replacement of alcohol with lorazepam helps prevent and/or minimize withdrawal symptoms, and it is the drug of choice to treat alcohol withdrawal-induced seizures. In the hospital s... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Drugs Used to Treat Alcohol Use Disorders**",
"Header 3": "**Lorazepam**",
"token_count": 471,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Nicotine is derived from the tobacco plant and has been in use for thousands of years. It is a highly addictive substance that facilitates great harm in clients who have nicotine use disorder (NUD). It is estimated that in the United States, more than 480,000 deaths are attributable to tobacco products, making it the n... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Nicotine Use**",
"token_count": 512,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Nicotine replacement therapy (NRT) is designed to replace the nicotine products that a client is currently using with products only containing nicotine. This helps reduce withdrawal symptoms and aids in the successful transition to using no nicotine. These come in a variety of dosage forms, including gums, patches, nas... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Nicotine (NicoDerm/Nicorette)**",
"token_count": 236,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Varenicline is a partial nicotine receptor agonist that has a greater affinity for the receptor than nicotine itself. Just as buprenorphine partially activates opioid receptors to reduce withdrawal symptoms and prevent other opioids from working as well, varenicline possesses the same actions for nicotine. Nicotine is ... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "**Nicotine (NicoDerm/Nicorette)**",
"Header 3": "**Varenicline**",
"token_count": 366,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- Alert their health care provider about any signs of allergic reactions, including throat swelling, severe itching, rash, or chest tightness.
- Notify their health care provider if palpitations, chest pain, anxiety, insomnia, and/or unintended weight loss occurs.
- Inform other health care providers that they are taki... | {
"Header 1": "UNFOLDING CASE STUDY",
"Header 2": "CLIENT TEACHING GUIDELINES",
"Header 3": "**The client taking a medication to treat nicotine use disorder should:**",
"token_count": 205,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- 16.1 [Introduction to the Heart, Circulation, and Blood Flow](#page-489-0)
- 16.2 [Pumping Action of the Heart](#page-492-0)
- 16.3 [Conduction of Electrical Impulses](#page-495-0)
**INTRODUCTION** Cardiovascular diseases are a group of conditions related to the heart and vasculature. It includes coronary heart dis... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**CHAPTER OUTLINE**",
"token_count": 374,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The heart is a fist-sized organ positioned in the central thoracic cavity, with the bulk of the heart to the left of the sternum. The heart is surrounded by a fibrous, layered sac called the pericardium. The pericardium protects the heart and provides a low-friction environment for the heart to pump in. The pericardium... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Anatomy of the Heart**",
"token_count": 833,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Blood circulates from the heart to every tissue of the body. This occurs through a network of **arteries**, **capillaries**, and **veins**. Generally, arteries carry oxygenated blood away from the heart and to the tissues (Arteries = Away). Arteries are thicker-walled blood vessels and give rise to systemic arterial pr... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Circulation and Blood Flow**",
"token_count": 430,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Systemic arterial pressure is pressure measured using a sphygmomanometer (blood pressure cuff) and is commonly just referred to as blood pressure. It is the pressure that can be measured in the arteries. It is dependent on both **cardiac output** (the amount of blood pumped from the left ventricle per unit of time) and... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Systemic Arterial Pressure**",
"token_count": 1052,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The heart pumps in a complex and coordinated cycle to move blood between the chambers of the heart, the lungs, and the associated blood vessels.
Ventricular systole (or just systole if not specified) refers to the active pumping or contraction of the ventricles. The contraction of the heart muscle increases pressure ... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**An Introduction to the Pumping Action of the Heart**",
"token_count": 560,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The cardiac cycle is a complex cycle that relies on pressure gradients and valves to direct blood through the heart and pulmonary circuit and into the systemic circulation. Blood flows from areas of higher pressure to areas of lower pressure based on pressure gradients, or differences in pressure among different spaces... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Cardiac Cycle**",
"token_count": 826,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Cardiac output is the amount of blood being pumped from the heart into the systemic circulation per unit of time. Cardiac output, systemic vascular resistance, and mean arterial pressure are related by the following formula:
As shown by this formula, cardiac output contributes to the mean arterial pressure. Cardiac o... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Cardiac Output and Hemodynamics**",
"token_count": 385,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Access multimedia content [\(https://openstax.org/books/pharmacology/pages/16-3-conduction-of-electrical](https://openstax.org/books/pharmacology/pages/16-3-conduction-of-electrical-impulses)[impulses\)](https://openstax.org/books/pharmacology/pages/16-3-conduction-of-electrical-impulses)
The National Heart, Lung, an... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "The Conduction System of the Heart",
"token_count": 479,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Automaticity describes a cell's ability to spontaneously generate an electrical impulse that allows it to function as the pacemaker of the heart. In a healthy heart, the sinoatrial node has an intrinsic rate of spontaneous impulses of 60–100 beats per minute (Kashou et al., 2022). The atrioventricular node, **bundle of... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "The Conduction System of the Heart",
"Header 3": "**Automaticity**",
"token_count": 252,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The cells of the cardiac conduction system receive the spontaneous impulses from the sinoatrial node and conduct, or carry, the signal through the atrioventricular node and then the bundle of His, which then splits into the left and right bundle branches. Each bundle branch gives rise to Purkinje fibers, which conduct ... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Conductivity**",
"token_count": 359,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The cardiac myocytes receive the electrical impulse from the conduction tissue and are stimulated to contract in a process called excitation-contraction coupling. During an action potential, calcium enters the cardiac myocyte via Ltype calcium channels and then interacts with receptors called ryanodine receptors on the... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Conductivity**",
"Header 3": "**Myocardial Contractility**",
"token_count": 238,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
When the cardiac electrical impulse is conducted in the direction of a lead, it creates an upward deflection; when traveling away, it causes a downward deflection. These are called **waveforms**. A segment on an ECG is the space between two waves and does not include a waveform. An interval, on the other hand, includes... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Electrocardiography**",
"Header 3": "**Waveforms**",
"token_count": 396,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Normal sinus rhythm is the normal rhythm of a healthy heart. This describes the scenario where the sinoatrial node causes the heart to beat at 60–100 beats per minute and at regular intervals (equal time between each heartbeat or ventricular contraction). On the electrocardiogram of a client in normal sinus rhythm, eve... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Electrocardiography**",
"Header 3": "**Dysrhythmias**",
"token_count": 266,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
- **action potential** rapid depolarization of the cell (i.e., the cell membrane potential increasing or becoming more positive as compared to its surroundings) followed by repolarization (i.e., the cell membrane potential decreasing back to the resting voltage)
- **afterload** the amount of systemic pressure that the ... | {
"Header 1": "CHAPTER 16 Introduction to the Cardiovascular System",
"Header 2": "**Key Terms**",
"token_count": 1676,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
17.1 [Introduction to Dysrhythmias](#page-503-0) 17.2 [Class I: Sodium Channel Blockers](#page-507-0) 17.3 [Class II: Beta Adrenergic Blockers](#page-511-0) 17.4 [Class III: Potassium Channel Blockers](#page-515-0) 17.5 [Class IV: Calcium Channel Blockers](#page-520-0) 17.6 [Unclassified Antidysrhythmics](#page-523-0) ... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**CHAPTER OUTLINE**",
"token_count": 500,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
**Dysrhythmia**s, also known as arrhythmias, occur when there is abnormal automaticity (spontaneous impulse generation) or abnormal conduction that results in a problem with the heart rate and/or rhythm. Medications address dysrhythmias by manipulating the electrolytes and other receptors involved in the cardiac conduc... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Dysrhythmias**",
"token_count": 397,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Atrial fibrillation is described as an irregularly irregular rhythm in which multiple areas of the atria generate spontaneous impulses such that the atria quiver at 400–600 beats per minute. Only some of the impulses are conducted through the AV node, resulting in a variable ventricular contraction rate or heart rate. ... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Dysrhythmias**",
"Header 3": "**Atrial Fibrillation**",
"token_count": 230,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Atrial flutter is a dysrhythmia closely related to atrial fibrillation. The atria quiver at rates of 250–400 beats per minute. As with atrial fibrillation, abnormal impulses are generated in the atria. Commonly, there is 2:1 conduction through the AV node, meaning that for every two impulses from the atria, one conduct... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Dysrhythmias**",
"Header 3": "**Atrial Flutter**",
"token_count": 206,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Ventricular fibrillation is a medical emergency that necessitates advanced cardiac life support (ACLS). This is another ventricular arrhythmia, meaning it originates from spontaneous impulses from the Purkinje fibers (rather than from an impulse carried from the SA node), causing the ventricles to quiver erratically ra... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Dysrhythmias**",
"Header 3": "**Ventricular Fibrillation**",
"token_count": 211,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Nonpharmacologic management of dysrhythmias depends on the specific dysrhythmia being treated and the clinical scenario. Lifestyle changes, procedures, and vagal maneuvers are all examples of nonpharmacologic management that can be attempted, depending on the client. In terms of lifestyle changes, clients can avoid or ... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Management of Cardiac Dysrhythmias**",
"Header 3": "**Nonpharmacologic Management**",
"token_count": 313,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Antidysrhythmic drugs treat abnormal heart rates and rhythms. They are often classified using the **Vaughan Williams classification system**, which differentiates drugs by their major mechanism of action [\(Table 17.1](#page-506-0)). However, this system is far from perfect. Many of the antidysrhythmic drugs have multi... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**Management of Cardiac Dysrhythmias**",
"Header 3": "**Pharmacologic Management**",
"token_count": 523,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
The risk of being diagnosed with dysrhythmia skyrockets after age 60. Not only does the risk for dysrhythmias increase, but older adults have a higher risk for concomitant disease states that interfere with the action of antidysrhythmic drugs. For example, beta-adrenergic blockers, quinidine, and procainamide can exace... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "Older Adults",
"token_count": 213,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
By the end of this section, you should be able to:
- 17.2.1 Identify the characteristics of the sodium channel blocker drugs used to treat dysrhythmias.
- 17.2.2 Explain the indications, actions, adverse reactions, and interactions of the sodium channel blocker drugs used to treat dysrhythmias.
- 17.2.3 Describe the ... | {
"Header 1": "CHAPTER 17 Antidysrhythmic Drugs",
"Header 2": "**LEARNING OUTCOMES**",
"token_count": 390,
"source_pdf": "datasets/websources/Med_v1/med_textbook/Pharmacology-WEB.pdf"
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.